BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34097939)

  • 1. The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinson's disease in C57BL/6 mice.
    Deng I; Wiese MD; Zhou XF; Bobrovskaya L
    Neurotoxicology; 2021 Jul; 85():254-264. PubMed ID: 34097939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson's Disease in C57BL/6 Mice.
    Deng I; Corrigan F; Garg S; Zhou XF; Bobrovskaya L
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-1β/IL-1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha-Synuclein pathology in the olfactory bulb, substantia nigra and striatum.
    Niu H; Wang Q; Zhao W; Liu J; Wang D; Muhammad B; Liu X; Quan N; Zhang H; Zhang F; Wang Y; Li H; Yang R
    Brain Pathol; 2020 Nov; 30(6):1102-1118. PubMed ID: 32678959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of Novel Formulations of Edaravone and Curcumin in the Mouse Intrastriatal Lipopolysaccharide Model of Parkinson's Disease.
    Deng I; Garg S; Zhou XF; Bobrovskaya L
    Front Biosci (Schol Ed); 2022 May; 14(2):13. PubMed ID: 35730438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice.
    Tanaka S; Ishii A; Ohtaki H; Shioda S; Yoshida T; Numazawa S
    J Neuroinflammation; 2013 Dec; 10():143. PubMed ID: 24289537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double triggers, nasal induction of a Parkinson's disease mouse model.
    Song G; Xi G; Li Y; Zhao Y; Qi C; Song L; Xiao B; Ma C
    Neurosci Lett; 2020 Apr; 724():134869. PubMed ID: 32114119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
    Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
    Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model.
    He Q; Li YH; Guo SS; Wang Y; Lin W; Zhang Q; Wang J; Ma CG; Xiao BG
    Eur J Neurosci; 2016 Jan; 43(1):41-52. PubMed ID: 26565388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
    Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
    Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
    J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function.
    Farrell KF; Krishnamachari S; Villanueva E; Lou H; Alerte TN; Peet E; Drolet RE; Perez RG
    J Neurochem; 2014 Feb; 128(4):536-46. PubMed ID: 24117685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the lipopolysaccharide induced model of Parkinson's disease: Role of oxidative stress and neuroinflammation.
    Sharma N; Nehru B
    Neurochem Int; 2015 Aug; 87():92-105. PubMed ID: 26055970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effect of Valeriana wallichii rhizome extract against the neurotoxin MPTP in C57BL/6 mice.
    Sridharan S; Mohankumar K; Jeepipalli SP; Sankaramourthy D; Ronsard L; Subramanian K; Thamilarasan M; Raja K; Chandra VK; Sadras SR
    Neurotoxicology; 2015 Dec; 51():172-83. PubMed ID: 26522450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
    Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
    Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
    Liu Y; Sun JD; Song LK; Li J; Chu SF; Yuan YH; Chen NH
    Behav Brain Res; 2015 Nov; 294():149-61. PubMed ID: 26239001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits.
    Liu Y; Qin L; Wilson B; Wu X; Qian L; Granholm AC; Crews FT; Hong JS
    Neurotoxicology; 2008 Sep; 29(5):864-70. PubMed ID: 18471886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.